We investigated controlled blood-brain barrier (BBB) disruption using a low-frequency clinical transcranial MRi-guided focused ultrasound (tcMRgfUS) device and evaluated enhanced delivery of irinotecan chemotherapy to the brain and a rat glioma model. Animals received three weekly sessions of FUS, FUS and 10 mg/kg irinotecan, or irinotecan alone. In each session, four volumetric sonications targeted 36 locations in one hemisphere. With feedback control based on recordings of acoustic emissions, 98% of the sonication targets (1045/1071) reached a pre-defined level of acoustic emission, while the probability of wideband emission (a signature for inertial cavitation) was than 1%. BBB disruption, evaluated by mapping the R1 relaxation rate after administration of an MRI contrast agent, was significantly higher in the sonicated hemisphere (P < 0.01). Histological evaluation found minimal tissue effects. Irinotecan concentrations in the brain were significantly higher (P < 0.001) with BBB disruption, but SN-38 was only detected in <50% of the samples and only with an excessive irinotecan dose. Irinotecan with BBB disruption did not impede tumor growth or increase survival. Overall these results demonstrate safe and controlled BBB disruption with a low-frequency clinical TcMRgFUS device. While irinotecan delivery to the brain was not neurotoxic, it did not improve outcomes in the F98 glioma model. Disrupting the blood-brain barrier (BBB) with focused ultrasound (FUS) and circulating microbubbles has been investigated to noninvasively and locally enhance drug delivery to the central nervous system 1. The method has been studied in numerous studies in animals 2-5 and has begun to be tested in humans to enhance chemotherapy delivery to brain tumors 6,7 and to reduce amyloid in Alzheimer's disease patients 8. While the exact mechanism of action is not fully understood, the disruption appears to arise via the mechanical interactions between the ultrasound field, the circulating microbubbles, and the vasculature that results in an opening of the BBB that lasts for several hours 9. FUS-induced BBB disruption has been shown to enable delivery of drugs, antibodies, nanoparticles, gene therapies, and even cells 10. Brain tumors do not have a fully-intact BBB. However, preclinical studies have shown that FUS can increase the permeability of the partially-intact blood-tumor barrier (BTB) and enhance the delivery of chemotherapy to CNS tumors 11-15. Perhaps more important is the prospect of getting drugs to surrounding areas where tumor cells are infiltrating into healthy brain where the BBB is intact. This infiltration, which often cannot be fully resected, leads to recurrence and is one of the main challenges in treating patients with brain tumors. BBB disruption is now being tested clinically 7,8,16. The ultrasound frequency used in clinical TcMRgFUS systems are lower than those used in most preclinical studies in rodents. A low frequency is used clinically to facilitate transmission through the thicker human skull. Reducing the ...